drugset
Drugs / NEU-111
last change Feb 2025 re-read 3 minutes ago

NEU-111

Investigated by
Neuron23 Inc.

Trials 1

today NCT06500442 · Ph 1
20252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06500442 Sep 2024 → Feb 2025 — Neuron23 Inc. Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2024-11-27 Neuron23 Inc. Neuron23 Announces First-in-human Dose in Phase 1 Clinical Trial of NEU-111, a TYK2 Inhibitor with Best-in-class Potential for Immune-mediated Inflammatory Disorders neuron23.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as NEU-111 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06500442 ↗
Route Oral “administered orally” NCT06500442 ↗